Neal Walker - 01 Feb 2025 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: INTERIM CEO, Director
Signature: /s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 01 Feb 2025
Net transactions value: -$8,826
Form type: 4
Filing time: 04 Feb 2025, 16:15:15 UTC
Previous filing: 03 Jan 2025
Next filing: 04 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+9,467	+0.65%		1,464,277	01 Feb 2025	Direct	F1
transaction	ACRS	Common Stock	Tax liability	$8,826	-3,559	-0.24%	$2.48	1,460,718	01 Feb 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-9,467	-25%	$0.000000	28,400	01 Feb 2025	Common Stock	9,467		Direct	F1, F3
transaction	ACRS	Restricted Stock Units	Award	$0	+253,900		$0.000000	253,900	03 Feb 2025	Common Stock	253,900		Direct	F1, F4
transaction	ACRS	Employee Stock Option (Right to Buy)	Award	$0	+888,800		$0.000000	888,800	03 Feb 2025	Common Stock	888,800	$2.40	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2	The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3	The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO.
F4	The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F5	Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.